| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgements
|
|
|
2013
|
|
1 |
p. 95-95
|
artikel
|
| 2 |
Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review
|
Schirren, Rebekka
|
|
2015
|
|
1 |
p. 39-48
|
artikel
|
| 3 |
Advances in thyroid cancer treatment: latest evidence and clinical potential
|
Alonso-Gordoa, T.
|
|
2015
|
|
1 |
p. 22-38
|
artikel
|
| 4 |
ALK inhibitors in non-small cell lung cancer: the latest evidence and developments
|
Sullivan, Ivana
|
|
2016
|
|
1 |
p. 32-47
|
artikel
|
| 5 |
An overview of the c-MET signaling pathway
|
Organ, Shawna Leslie
|
|
2011
|
|
1 |
p. S7-S19
|
artikel
|
| 6 |
Anti-programmed death receptor 1 immunotherapy in melanoma: rationale, evidence and clinical potential
|
Freeman-Keller, Morganna
|
|
2015
|
|
1 |
p. 12-21
|
artikel
|
| 7 |
Clinicopathologic characteristics and management trends of cutaneous invasive and in situ melanoma in older patients: a retrospective analysis of the National Cancer Data Base
|
Bhatt, Vijaya Raj
|
|
2015
|
|
1 |
p. 4-11
|
artikel
|
| 8 |
c-MET: an exciting new target for anticancer therapy
|
de Bono, Johann S.
|
|
2011
|
|
1 |
p. S3-S5
|
artikel
|
| 9 |
c-MET as a potential therapeutic target and biomarker in cancer
|
Sierra, J. Rafael
|
|
2011
|
|
1 |
p. S21-S35
|
artikel
|
| 10 |
Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
|
Eroglu, Zeynep
|
|
2016
|
|
1 |
p. 48-56
|
artikel
|
| 11 |
Combining Notch inhibition with current therapies for breast cancer treatment
|
Brennan, Keith
|
|
2013
|
|
1 |
p. 17-24
|
artikel
|
| 12 |
Correlation between NAD(P)H: quinone oxidoreductase 1 C609T polymorphism and increased risk of esophageal cancer: evidence from a meta-analysis
|
Diao, Jingfang
|
|
2017
|
|
1 |
p. 13-21
|
artikel
|
| 13 |
Current and future options in the management and treatment of uterine sarcoma
|
El-Khalfaoui, Khalid
|
|
2014
|
|
1 |
p. 21-28
|
artikel
|
| 14 |
Editorial
|
Coombes, R. Charles
|
|
2009
|
|
1 |
p. 3-3
|
artikel
|
| 15 |
Epithelial–mesenchymal transition in pulmonary carcinosarcoma: case report and literature review
|
Thomas, Vibha T.
|
|
2012
|
|
1 |
p. 31-37
|
artikel
|
| 16 |
Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians
|
Wang, Yongsheng
|
|
2012
|
|
1 |
p. 19-29
|
artikel
|
| 17 |
European Society for Medical Oncology Copenhagen update: potential practice-changing findings
|
Mallarkey, Gordon
|
|
2017
|
|
1 |
p. 4-12
|
artikel
|
| 18 |
Future directions in the evaluation of c-MET-driven malignancies
|
de Bono, Johann S.
|
|
2011
|
|
1 |
p. S51-S60
|
artikel
|
| 19 |
Immunotherapy updates in pancreatic cancer: are we there yet?
|
Gunturu, Krishna Soujanya
|
|
2013
|
|
1 |
p. 81-89
|
artikel
|
| 20 |
Incorporating VEGF-targeted therapy in advanced urothelial cancer
|
Narayanan, Sujata
|
|
2017
|
|
1 |
p. 33-45
|
artikel
|
| 21 |
In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs
|
Sharma, Neelesh
|
|
2011
|
|
1 |
p. S37-S50
|
artikel
|
| 22 |
Latest advances in medical oncology: highlights from Milan ESMO 2010 annual congress
|
Mallarkey, Gordon
|
|
2011
|
|
1 |
p. 3-9
|
artikel
|
| 23 |
Latest advances in the medical treatment of cancer: a 2011 snapshot
|
Mallarkey, Gordon
|
|
2012
|
|
1 |
p. 3-8
|
artikel
|
| 24 |
Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications
|
Gentzler, Ryan D.
|
|
2014
|
|
1 |
p. 4-15
|
artikel
|
| 25 |
Management of anaemia in oncohaematological patients treated with biosimilar epoetin alfa: results of an Italian observational, retrospective study
|
Rosti, Giovanni
|
|
2017
|
|
1 |
p. 22-32
|
artikel
|
| 26 |
New agents on the horizon in hepatocellular carcinoma
|
Zhu, Andrew X.
|
|
2013
|
|
1 |
p. 41-50
|
artikel
|
| 27 |
New treatment approaches in melanoma: current research and clinical prospects
|
Rughani, Milap G.
|
|
2013
|
|
1 |
p. 73-80
|
artikel
|
| 28 |
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
|
Wurz, Gregory T.
|
|
2016
|
|
1 |
p. 4-31
|
artikel
|
| 29 |
Pharmacologic resistance in colorectal cancer: a review
|
Hammond, William A.
|
|
2016
|
|
1 |
p. 57-84
|
artikel
|
| 30 |
Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data
|
Kishan, Amar U.
|
|
2016
|
|
1 |
p. 85-97
|
artikel
|
| 31 |
Prolyl isomerase Pin1 and neurotrophins: a loop that may determine the fate of cells in cancer and neurodegeneration
|
Angelucci, Francesco
|
|
2017
|
|
1 |
p. 59-62
|
artikel
|
| 32 |
Review: Advanced non-small cell lung cancer: the role of maintenance therapy
|
Agarwala, Anuj K.
|
|
2010
|
|
1 |
p. 17-23
|
artikel
|
| 33 |
Review: Balancing the efficacy and toxicity of chemotherapy in colorectal cancer
|
Braun, Michael S.
|
|
2011
|
|
1 |
p. 43-52
|
artikel
|
| 34 |
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
|
Stein, Alexander
|
|
2010
|
|
1 |
p. 51-63
|
artikel
|
| 35 |
Review: Neoadjuvant chemoradiotherapy has a potential role in pancreatic carcinoma
|
van Tienhoven, Geertjan
|
|
2011
|
|
1 |
p. 27-33
|
artikel
|
| 36 |
Review: Novel agents for advanced bladder cancer
|
Sonpavde, Guru
|
|
2009
|
|
1 |
p. 37-50
|
artikel
|
| 37 |
Review: Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective
|
Poultsides, George A.
|
|
2011
|
|
1 |
p. 35-42
|
artikel
|
| 38 |
Review: Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence
|
Lee, Francis
|
|
2011
|
|
1 |
p. 11-25
|
artikel
|
| 39 |
Review: Systemic therapy for advanced renal cell carcinoma
|
Larkin, James M.G.
|
|
2009
|
|
1 |
p. 15-27
|
artikel
|
| 40 |
Review: Targeted therapies in small cell lung cancer: a review
|
Abidin, Aidalena Z.
|
|
2010
|
|
1 |
p. 25-37
|
artikel
|
| 41 |
Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions
|
Heng, Daniel Y.C.
|
|
2010
|
|
1 |
p. 39-49
|
artikel
|
| 42 |
Review: The potential role of bevacizumab in early stages and locally advanced non-small cell lung cancer
|
Schettino, Clorinda
|
|
2009
|
|
1 |
p. 5-13
|
artikel
|
| 43 |
Review: Therapeutic opportunities in noncutaneous melanoma
|
Wilkins, D.K.
|
|
2009
|
|
1 |
p. 29-36
|
artikel
|
| 44 |
Review: Thyroid cancer: emerging role for targeted therapies
|
Sipos, Jennifer A.
|
|
2010
|
|
1 |
p. 3-16
|
artikel
|
| 45 |
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients
|
Deenen, Maarten J.
|
|
2013
|
|
1 |
p. 91-92
|
artikel
|
| 46 |
Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential
|
Delbaldo, Catherine
|
|
2012
|
|
1 |
p. 9-18
|
artikel
|
| 47 |
Targeted approach to metastatic colorectal cancer: what comes beyond epidermal growth factor receptor antibodies and bevacizumab?
|
Troiani, Teresa
|
|
2013
|
|
1 |
p. 51-72
|
artikel
|
| 48 |
Targeted therapies in medical oncology: successes, failures and next steps
|
Mallarkey, Gordon
|
|
2013
|
|
1 |
p. 5-16
|
artikel
|
| 49 |
Taxanes: vesicants, irritants, or just irritating?
|
Barbee, Meagan S.
|
|
2014
|
|
1 |
p. 16-20
|
artikel
|
| 50 |
Tegafur-uracil (UFT) in lower doses is safe for the treatment of colorectal cancer in patients with partial dihydropyrimidine dehydrogenase deficiency: a proof of principle
|
Cubero, Daniel I. G.
|
|
2013
|
|
1 |
p. 93-94
|
artikel
|
| 51 |
The changing landscape in the treatment of metastatic castration-resistant prostate cancer
|
El-Amm, Joelle
|
|
2013
|
|
1 |
p. 25-40
|
artikel
|
| 52 |
Therapeutic approach to treating patients with BRAF-mutant lung cancer: latest evidence and clinical implications
|
de Langen, Adrianus J.
|
|
2017
|
|
1 |
p. 46-58
|
artikel
|
Tijdschrift beschrijving